600513 Stock Overview
Manufactures and sells pharmaceuticals, preparations, and API products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.40 |
| 52 Week High | CN¥13.01 |
| 52 Week Low | CN¥6.71 |
| Beta | 0.35 |
| 1 Month Change | 2.97% |
| 3 Month Change | 23.37% |
| 1 Year Change | -3.97% |
| 3 Year Change | 11.71% |
| 5 Year Change | 33.50% |
| Change since IPO | 5.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.9% | -3.1% | -2.1% |
| 1Y | -4.0% | -4.4% | 9.8% |
Return vs Industry: 600513 matched the CN Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: 600513 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 600513 volatility | |
|---|---|
| 600513 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 600513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600513's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,296 | Ben Niu | www.lhpharma.com |
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and API products in China and internationally. The company offers clopidogrel bisulfate tablets to prevent atherothrombotic events; doxycycline hydrochloride tablets for upper respiratory tract infections, tonsilitis, biliary tract infections, lymphadenitis, cellulitis, and chronic bronchitis; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; dapoxetine hydrochloride tablets to treat premature ejaculation; tadafil tablets for erectile dysfunction; and bepotastine besilate tablets. It also provides aiplete tablets to treat benign prostatic hyperplasia; ebastine tablets for allergic rhinitis; felodipine tablets for mild to moderate essential hypertension; drotaverine hydrochloride injection to treat smooth muscle spasms caused by gastrointestinal diseases and to relieve dysmenorrhea; danazol suppositories to treat endometriosis; and terfenadine tablets for allergic rhinitis, perennial allergic rhinitis, and acute and chronic urticaria, as well as preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics.
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Fundamentals Summary
| 600513 fundamental statistics | |
|---|---|
| Market cap | CN¥2.97b |
| Earnings (TTM) | CN¥138.87m |
| Revenue (TTM) | CN¥2.34b |
21.4x
P/E Ratio1.3x
P/S RatioIs 600513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600513 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.34b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥1.17b |
| Other Expenses | CN¥1.03b |
| Earnings | CN¥138.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 49.96% |
| Net Profit Margin | 5.95% |
| Debt/Equity Ratio | 51.7% |
How did 600513 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 02:30 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Lianhuan Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|